**Core Concept**
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) that mimics estrogenic effects in some tissues while antagonizing estrogenic effects in others. It is used in the treatment and prevention of osteoporosis in postmenopausal women and also has a role in breast cancer prevention.

**Why the Correct Answer is Right**
Venous thromboembolism (VTE) is a known risk associated with estrogen therapy, particularly in postmenopausal women. Raloxifene, on the other hand, does not increase the risk of VTE and may even have a protective effect against it. This is because raloxifene has a different pharmacological profile compared to estrogen, which makes it a safer alternative for postmenopausal women at risk of VTE.

**Why Each Wrong Option is Incorrect**
**Option A:** Raloxifene does indeed reduce fracture rates by mimicking estrogenic effects on bone, making it an effective treatment for osteoporosis in postmenopausal women.
**Option B:** Raloxifene avoids endometrial hyperplasia, a known risk associated with estrogen therapy, because it has anti-estrogenic effects on the endometrium, thereby protecting against this condition.
**Option D:** Raloxifene reduces the risk of invasive breast cancer by blocking estrogen receptors in breast tissue, which is a key mechanism of its breast cancer prevention effects.

**Clinical Pearl / High-Yield Fact**
When choosing between estrogen and raloxifene for postmenopausal women, it is essential to consider the patient's risk factors for VTE, as raloxifene may be a safer alternative in these cases.

**✓ Correct Answer: C. Reduces incidence of venous thrombosis**